Aoife Carr

Dublin, L, Ireland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

RETRACTED: Richards et al. Protein Tyrosine Phosphatase Non-Receptor 11 (PTPN11/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC). Int. J. Mol. Sci. 2023, 24, 10545.

RETRACTED: Richards et al. Protein Tyrosine Phosphatase Non-Receptor 11 (PTPN11/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC). Int. J. Mol. Sci. 2023, 24, 10545.

Journal: International journal of molecular sciences

Published: March 23, 2026

Targeting the phosphatidylinositol-3-kinase (PI3K) and mitogen activated protein kinase (MAPK) signalling pathways to enhance chemoradiotherapy in locally advanced rectal cancer.

Targeting the phosphatidylinositol-3-kinase (PI3K) and mitogen activated protein kinase (MAPK) signalling pathways to enhance chemoradiotherapy in locally advanced rectal cancer.

Journal: Cancer treatment and research communications

Published: October 15, 2024

Preclinical evaluation of the CDK4/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer.

Preclinical evaluation of the CDK4/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer.

Journal: Cancer biology & therapy

Published: June 16, 2023

RETRACTED: Protein Tyrosine Phosphatase Non-Receptor 11 (PTPN11/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC).

RETRACTED: Protein Tyrosine Phosphatase Non-Receptor 11 (PTPN11/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC).

Journal: International journal of molecular sciences

Published: May 03, 2023

The prevalence of hypertension in paediatric Turner syndrome: a systematic review and meta-analysis.

The prevalence of hypertension in paediatric Turner syndrome: a systematic review and meta-analysis.

Journal: Journal of human hypertension

Published: April 29, 2022

Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer.

Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer.

Journal: Journal of translational medicine

Published: February 10, 2021

Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer "PantHER".

Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer "PantHER".

Journal: Cancers

Published: January 30, 2021

Genomic and Transcriptomic Characterisation of Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer.

Genomic and Transcriptomic Characterisation of Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer.

Journal: Cancers

Published: May 28, 2020

Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer.

Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer.

Journal: Obstetrics & gynecology science

Published: February 04, 2020

Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples.

Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples.

Journal: Journal of translational medicine

Published: September 06, 2019

Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH).

Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH).

Journal: PloS one

Published: February 12, 2018

Frequency, impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer.

Frequency, impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer.

Journal: Therapeutic advances in medical oncology

Published: November 19, 2017

Showing 1-12 of 16

Last Updated: 09/26/2026